

PRODUCT INFORMATION



C16 Ganglioside G_{M2}-d₉ (d18:1/16:0-d₉) (ammonium salt)

Item No. 31196

CAS Registry No.: 2750534-90-6

Formal Name: N-[(1S,2R,3E)-1-[[[O-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl-(1→4)-O-[N-acetyl-α-neuraminosyl-(2→3)]-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide-13,13,14,14,15,15,16,16,16-d₉, monoammonium salt

Synonyms: C16 G_{M2}-d₉, N-CD₉-Palmitoyl-G_{M2}, N-Hexadecanoyl-d₉ (13,13,14,14,15,15,16,16,16)-Monosialoganglioside G_{M2}, N-Palmitoyl Monosialoganglioside G_{M2}-d₉

MF: C₆₅H₁₀₇D₉N₃O₂₆ • NH₄

FW: 1,382.7

Chemical Purity: ≥95% (C16 Ganglioside G_{M2})


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₉); ≤1% d₀

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C16 Ganglioside G_{M2}-d₉ (d18:1/16:0-d₉) (ammonium salt) is intended for use as an internal standard for the quantification of C16 ganglioside G_{M2} by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Description

C16 Ganglioside G_{M2} (d18:1/16:0) is a monosialated ganglioside.¹ It has been found in A2780 ovarian carcinoma cells, as well as purified ganglioside mixtures extracted from healthy postmortem and hemangioma-bearing human frontal lobe cortical tissue.^{1,2} As this product is derived from a natural source, there may be variations in the sphingoid backbone.

References

1. Schiopu, C., Flangea, C., Capitan, F., *et al.* Determination of ganglioside composition and structure in human brain hemangioma by chip-based nanoelectrospray ionization tandem mass spectrometry. *Anal. Bioanal. Chem.* **395**(8), 2465-2477 (2009).
2. Valsecchi, M., Aureli, M., Mauri, L., *et al.* Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. *J. Lipid Res.* **51**(7), 1832-1840 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM